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1. Introduction 
The prevalence of diabetes is increasing globally and the total number of people with this 
condition is projected to rise from 171 million in 2000 to 366 million in 2030 (Wild et al, 
2004). India is no exception, with projected rates of 79.4 million in 2030—a 151% increase 
from 31.7 million in 2000 (Wild et al, 2004). The increased prevalence is attributed to the 
aging population structure, urbanization, the obesity epidemic, and physical inactivity 
(Hunt & Schuller, 2007). While all these factors contribute to the epidemic of diabetes, 
intrauterine exposures are emerging as potential risk factors (Barker, 1995). The “fetal origin 
of adult disease” hypothesis proposes that gestational programming may critically influence 
adult health and disease (Barker, 1995). Gestational programming is a process whereby 
stimuli or stresses occurring at critical or sensitive periods of fetal development, 
permanently change structure, physiology, and metabolism, which predisposes individuals 
to disease in adult life (Lucas, 1991). If the stimulus happens to be glucose intolerance in 
pregnancy, it predisposes the offspring to an increased risk of developing glucose 
intolerance in the future. This vicious cycle is likely to influence and perpetuate the 
incidence and prevalence of glucose intolerance in any population (Seshiah et al., 2004). 
Therefore, preventive measures against type 2 diabetes should start during the intrauterine 
period and continue from early childhood throughout life (Tuomilehto, 2005). In this 
respect, detection of gestational diabetes mellitus (GDM), defined as carbohydrate 
intolerance of variable severity with onset or first recognition during the present pregnancy 
(Metzger, 1991), becomes an important public health issue. The etiopathogenesis of glucose 
intolerance that develops in women with GDM could be the result of their inability to 
increase insulin secretion enough to overcome insulin resistance that occurs even in non 
diabetic pregnancy (Kuhl et al., 1985). The present concept is that GDM represents, detection 
of chronic β cell dysfunction, rather than development of relative insulin deficiency as 
insulin resistance increases during pregnancy (Buchanan et al., 2007).  
2. Implications 
The usual recommendation of lifestyle modifications or drug intervention for prevention of 
diabetes is likely to delay or postpone the development of overt diabetes in persons 
diagnosed with abnormal glucose tolerance. These measures essentially target only the post 
primary prevention of diabetes whereas the aim should be primary prevention of diabetes 
by keeping the genetically or otherwise susceptible individuals normoglycemic, apart from 
preventing them from developing type 2 DM (Tuomilehto, 2005).  In this context, women 
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with GDM become the ideal group for primary prevention of diabetes (Girling & Dornhorst, 
2003), as women with GDM are at increased risk of developing diabetes predominantly type 
2 DM as are their children (Dornhorst & Rossi, 1998). The diagnosis of GDM offers a unique 
opportunity in identifying individuals who will be benefited by early therapeutic 
intervention with diet and exercise, thus normalizing the weight to delay or even possibly 
prevent the onset of diabetes.    
3. Prevalence  
The epidemiology of GDM is subject to various factors such as the population to be screened, 
the screening methods, the gestational weeks for screening and the glycemic criteria for 
diagnosis. Screening recommendations range from inclusion of all pregnant women 
(universal) to the exclusion of all other women except those with very specific risk factors 
(selective): (e.g., age > 25 years, obesity: BMI > 30, ethnicity: Hispanic, Native American, 
Asian-American, African-American, family history: first degree relative, and previous GDM or 
large for gestational age infant) (Mazze, 2006). Different ethnic groups when exposed to the 
same environmental setting, experienced a widely variable risk. Among ethnic groups in 
South Asian countries, Indian women have the highest frequency of GDM (15%), followed by 
Chinese (13.9%), Vietnam-born (7.8%) and Australian-born (4.3%)  (King, 1998).  
For a given population and ethnicity, the risk of diabetes in pregnancy, mirrors that of the 
underlying frequency of type 2 DM in that population (King, 1998). Impaired Glucose 
Tolerance (IGT) is generally much more prevalent than diabetes in women of child bearing 
age (King, 1998). Among Indians, the prevalence of IGT in the age group of 20 to 29 years 
and 30 to 39 years was found to be 12.2% and 15.3% respectively. No gender difference was 
seen in the prevalence of IGT (Ramachandran et al., 2001). It was observed in a national 
survey performed in 2002, the frequency of the occurrence of GDM was 16.55% by the 
World Health Organization (WHO) criteria (Seshiah et al., 2004) which was closer to the 
prevalence of IGT in the child-bearing age group of women in India (Ramachandran et al., 
2001). Parallel to the increased prevalence of IGT in the general population, the frequency of 
GDM had also increased. The prevalence of GDM was 2% in 1982 (Agarwal & Gupta, 1982) 
[IGT - 2% (Ramachandran et al., 1988)] which increased to 7.62% in 1991 (Narendra et al., 
1991) [IGT – 8.2% (Ramachandran et al., 1992)], and doubled to 16.55% in 2002 (Seshiah et 
al., 2004) [IGT – 14.5% (Ramachandran et al., 2001)]. The prevalence data published (Seshiah 
et al., 2004) included pregnant women attending different health care providing centres 
spread in different parts of the country (Table – 1).  
This phenomenal increase in the prevalence of GDM prompted the authors to initiate a 
project on ‘Diabetes In Pregnancy Awareness and Prevention (DIPAP)’, funded by the 
World Diabetes Foundation and supported by the government of Tamil Nadu, India. To 
have a community based prevalence data under the DIPAP project, the author’s group 
screened a total of 4151, 3960 and 3945 pregnant women in the urban, semi urban and rural 
areas of Tamil Nadu, respectively (Seshiah et al., 2008a). This was the largest prospective 
study (N=12,056) other than Hyperglycemia and Adverse Pregnancy Outcome (HAPO) 
study. GDM diagnosis was based on the WHO criterion of 2-h plasma glucose (PG) ≥ 7.8 
mmol/L with 75g oral glucose. WHO recommendation serves both as one step screening 
and diagnostic procedure, and is easy to perform besides being economical (Seshiah et al., 
2004, 2005). WHO criterion of 2-h PG ≥ 7.8 mmol/L identifying a large number of cases may 
have a greater potential for prevention (Schmidt et al., 2001). In addition, a study performed by  
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 Centre 
Number of 
pregnant women 
screened 
Prevalence Rate 
Dr. Balaji et al 
North Chennai, 
Tamil Nadu 
891 16.2% 
Dr. Anjalakshi et al 
South Chennai, 
Tamil Nadu 
1002 15% 
Dr. K. P. Paulose Trivandrum, Kerala 750 15% 
Dr. Mary John Ludhiana, Punjab 220 17.5% 
Dr. Prasanna Kumar Bangalore, Karnataka 49 12% 
Dr. Shyam Mukundan Alwaye, Kerala 200 21% 
Dr. Aruyerchelvan 
Erode, 
Tamil Nadu 
562 18.8% 
 TOTAL 3674 16.55% 
Table 1. Prevalence of GDM in different parts of India – 2002 
Crowther et al found that treatment of GDM diagnosed by WHO criterion reduces serious 
perinatal morbidity and may also improve the women’s health-related quality of life 
(Crowther at al., 2005). Similarly a long term outcome study conducted by Franks et al 
documented that when maternal 2-h PG was ≥ 7.8 mmol/L, the cumulative risk of offspring 
developing type 2 DM was 30% at the age 24 yrs (Franks et al., 2006). Both these short term 
and long term outcome studies validate the WHO criterion and hence the authors chose this 
criterion for the DIPAP project. In this project GDM was detected in 739 (17.8%) women in 
urban, 548 (13.8%) in semi urban and 392(9.9%) in rural areas. In this community based study, 
the overall prevalence of GDM was 13.9% (Seshiah et al., 2008a). The prevalence of GDM had 
increased from 16.55% to 17.8% in the urban areas in two years (Seshiah et al., 2004, 2008a). 
There is a definite divide between the rural and urban areas in the prevalence of GDM. The 
possible cause for the low prevalence in the rural settings may be due to the less mechanized, 
agriculture based lifestyle. In this population the risk factors for the development of GDM 
were: age ≥ 25 years, BMI ≥ 25 and family history of diabetes (Figure 1).    
 
 
Fig. 1. Risk factors for the development of GDM 
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3.1 Geographical variations in the prevalence of GDM 
Prevalence varies between 1% to 16% depending on the geographical variation and ethnicity 
and from one region to another in the same country (Yogev et al., 2003). The prevalence of 
GDM corresponds to the prevalence of IGT within a given population (King, 1998). The 
prevalence of GDM in India was 16.55% in the urban area and the frequency varied from 12% 
to 21% in different parts of the country (Seshiah et al., 2004) (Table 1). A low prevalence of 
GDM was observed in Kashmir (Zargar et al., 2004) (northern tip of India) 4.4% and a high 
prevalence of 16.55% in the southern part of India (Seshiah et al., 2004). The prevalence of 
GDM in other developing countries also showed regional variations. In Mexico, the prevalence 
of GDM varied from 4.3% to 11% when screening was done in different parts of the country 
(Forsbach et al., 1998).  The rate of abnormal screening test results ranged from 8.0% to 20.7% 
for different regions of Poland (Wojcikowski et al, 2002). Among Pan Arab countries, Saudi 
Arabia (12.5%) and Bahrain (13.5%) had the highest prevalence of GDM (Al Mahroos et al, 
2005; Ardawi et al, 2000). The frequency of GDM in Argentina was between 2% and 12% 
depending upon the population studied and geographical variations (Liliana et al, 2003).  
4. Rationale for universal screening 
Selective screening based on risk factors scored poorly in predicting GDM (Shamsuddin et 
al, 2001). If selective screening is employed, it is likely that 27% of GDM women will go 
undetected (Shamsuddin et al, 2001). GDM diagnosis is overlooked in about 1/3rd of the 
women, where selective rather than Universal screening is performed (Cosson et al., 2004a). 
Further selective screening recommended by American Diabetes Association (ADA) may be 
applicable for women belonging to the ethnic group with low prevalence of GDM.  Risk 
factor screening does not take into account the inevitable difficulties in implementation, 
including the potential for substantial under-diagnosis of GDM (Simmons et al., 2009). 
Among ethnic groups in South Asian countries, Indian women have the highest frequency 
of GDM necessitating Universal Screening (Beischer et al., 1991). The recognition of glucose 
intolerance during pregnancy is more relevant as Indian women have 11 fold increased risk 
of developing GDM compared to Caucasians (Dornhorst et al., 1992).  
Compared to selective screening, Universal screening for GDM detects more cases and 
improves maternal and offspring prognosis (Cosson, 2004b). Thus Universal screening 
appears to be the most reliable and desired method for the detection of GDM (Shamsuddin et 
al., 2001). For universal screening the test should be simple and cost effective. The two step 
procedure of screening with 50g Glucose challenge test (GCT) and then diagnosing GDM 
based on 75g OGTT is not feasible in a country like India, because the pregnant women may 
have to visit the antenatal clinic twice and at least 3 to 5 blood samples have to be drawn, 
which they resent. The scenario is likely to be the same in most of the developing countries.  
5. Diagnosis of GDM 
5.1 A single step procedure to diagnose GDM 
All the diagnostic criteria require women to be in fasting, but most of the time pregnant 
women do not come in the fasting state because of commutation and belief not to fast for 
long hours. Attending the first prenatal visit in the fasting state is impractical in many 
settings (Metzger et al., 2010). The dropout rate is very high when a pregnant woman is 
asked to come again for the glucose tolerance test (Seshiah et al., 2004; Magee et al., 2001).  
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For the successful implementation of universal screening, a test has to be casual and reliable. 
A procedure that does not impose any restriction would be ideal for universal screening. 
The test performed should be able to diagnose GDM, as they walk into the prenatal clinic or 
clinical laboratory irrespective of their last meal timings. Hence the authors undertook a 
study to evaluate, whether a 2-h 75g oral glucose test performed in a non-fasting state, 
irrespective of last meal timing, is as efficacious as 2-h 75g oral glucose test done in the 
fasting state recommended by WHO in detecting GDM (Anjalakshi et al., 2009). A total of 
862 consecutive pregnant women were subjected to 75g oral glucose test irrespective of time 
of the last meal. Venous samples were collected at 2-h after oral glucose administration. 
They were advised to follow a diet containing atleast 150g carbohydrate daily and usual 
activity for atleast 3 days and come to the prenatal clinic after an overnight fasting of 10-12 
h. At the second visit 800 of them responded and underwent 2-h 75g oral glucose test in the 
fasting state recommended by WHO. The observation in this study was, all women 
diagnosed as GDM (N=87) by 75g glucose test irrespective of the last meal timings also 
satisfied the diagnostic criteria of 75-g oral glucose test performed in the fasting state 
recommended by WHO. It was also found that there was no statistically significant 
difference (P > 0.05) between the PG levels of the 75g glucose test in fasting and non fasting 
state, irrespective of last meal timing, performed in the GDM and in NGT pregnant women. 
The rationale behind this study outcome is that, a normal glucose tolerant woman would be 
able to maintain euglycemia despite glucose challenge due to adequate insulin response, 
whereas in a woman with GDM who has impaired insulin secretion (Kuhl, 1991), her 
glycemic level increases with a meal and with glucose challenge, the glycemic excursion is 
expected to exaggerate. This cascading effect is advantageous as this would not result in 
false positive diagnosis of GDM. Performing this test procedure in the non-fasting state,  
irrespective of last meal timing, is prudent as glucose concentrations during the glucose 
tolerance are affected little by the time since the last meal (Gough et al., 1970). 
Pettitt et al. observed that WHO criteria based on the glucose concentration 2-h after 75g 
oral glucose administered to non-fasting women correctly identified subjects with GDM 
(Pettitt et al., 1994). The non-fasting 2-h post 75g glucose concentration strongly predicts 
adverse outcome for the mother and her offspring (Pettitt et al., 1991). Philips et al also 
observed that plasma glucose value with a glucose challenge test was unaffected by the time 
after a meal or time of the day in Normal Glucose Tolerant non pregnant subjects (Philips et 
al., 2009). Thus, this single test procedure performed irrespective of the last meal timing is 
rational and a patient friendly approach, which causes least disturbance in her routine 
activities. This procedure is a modified version of WHO criteria in that, only 2-h PG is taken 
into consideration for the diagnosis of GDM and is being followed by the Diabetes In 
Pregnancy Study Group India (DIPSI) (Seshiah et al., 2009) 
5.2 Comparison of WHO and IADPSG criteria 
All the diagnostic criteria, except the existing diagnostic criterion of WHO 2-h plasma 
glucose (PG) ≥ 7.8 mmol/L with 75g oral glucose load (King, 1998), are country specific or 
recommended by various associations. Recently, based on the HAPO study, the 
International Association of Diabetes and Pregnancy Study Groups (IADPSG) consensus 
panel recommended that GDM can be diagnosed, if any one value of fasting plasma glucose 
(FPG), 1-h and 2-h PG concentrations meet or exceed 5.1 mmol/L, 10.0 mmol/L and 8.5 
mmol/L respectively, with 75g oral glucose tolerance test (OGTT) (Metzger et al., 2010).  
India one of the most populous countries in the world was not part of the HAPO study. 
Hence the authors group undertook a prospective, collaborative study to ascertain whether 
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the present practice of diagnosing GDM by the guidelines recommended by Diabetes In 
Pregnancy Study Group India (DIPSI) (Seshiah et al., 2009) based on WHO criterion of 2-h 
PG ≥ 7.8 mmol/L can still be followed in India or adopt IADPSG recommendations. A total 
of 1,463 consecutive pregnant women with no previous history of GDM/pre GDM 
underwent a 75g OGTT and fasting, 1-h and 2-h PG were measured. Using the DIPSI 
criterion, 196 (13.4%) women were diagnosed as GDM. By applying IADPSG 
recommendation the cumulative prevalence of GDM was 14.6% (n=214). There was no 
significant difference (P > 0.05) in the discordant pair of diagnosing GDM by the two criteria 
which in turn implies, that the disagreement in diagnosing GDM by both criteria was not 
significant (P = 0.21, by Mc Nemar test). The difference in the diagnostic capability between 
IADPSG and DIPSI was 1.2% which was not significant (P>0.02) (Seshiah et al., 2011). IADPSG 
recommendation necessarily requires estimation of PG in three blood samples after 
administrating 75g oral glucose load. Pregnant women despise this procedure, as venous 
blood is drawn three times and they feel too much of blood is drained. Whereas, DIPSI 
criterion requires one blood sample drawn at 2-h following a 75g glucose load for estimating 
the PG. The cost involved in performing IADPSG recommended procedure is high, as this 
procedure requires three blood tests compared to one blood test of DIPSI. The cost will 
escalate further, if IADPSG diagnostic procedure is performed in each trimester in high risk 
population in whom GDM manifests in all trimesters of pregnancy (Seshiah et al., 2007). 
Among women with normal OGTT results in the first visit when tested in the subsequent 
visits, 28% of them were detected to have GDM (Seshiah et al., 2007). Hence, DIPSI procedure 
based on WHO criterion is feasible, sustainable, cost-effective and best buy to diagnose GDM 
in any country and particularly in less resource nations. IADPSG recommendations are 
suitable in clinical settings where financial and technical supports are available. The 
performance of both IADPSG and WHO criteria are similar as per GRADE ratings. 
5.3 Inadequacy of fasting plasma glucose to diagnose GDM 
The IADPSG criteria suggests FPG ≥ 5.1 mmol/L but ≤ 7.0 mmol/L to diagnose GDM in the 
first prenatal visit (Metzger et al., 2010) whereas the authors observed in their study that by 
applying this criterion of FPG ≥ 5. 1 mmol/L, only 24% (3.2% of the total population) of 
those diagnosed as GDM using WHO criterion 2-h PG ≥ 7.8 mmol/L would have been 
classified as GDM (Balaji et al., 2011a). Further, FPG of 5.1 mmol/L was not able to diagnose 
GDM in comparison to 2-h PG ≥ 7.8 mmol/L (Table 2). This is due to the ethnicity of Asian 
Indians who have high insulin resistance (IR) and as a consequence, their postprandial 
plasma glucose is higher compared to Caucasians (Mohan et al., 2007; Snehalatha et al., 
2009). Asian and South Asian ethnicity are both independently associated with increased IR 
in late pregnancy (Retnakaran et al., 2006). Siddhartha Das et al documented an increased IR 
during pregnancy in Asian Indian Women and IR escalates further in GDM (Das et al., 
2010). These studies provide evidence that FPG may not be an appropriate option to 
diagnose GDM in Asian Indian women.  Further, in all GDM, the FPG values do not reflect 
the postprandial hyperglycemia (Valensi et al., 2009), which is the hallmark of GDM (Weiss 
et al., 2000). In addition, there is a paucity of data regarding the reproducibility of the FPG 
test (Sacks et al., 2010). Hence, administering 75g oral glucose load and measuring 2-h PG 
serves as a one-step definitive procedure to diagnose GDM in less serviced regions. 
Perucchini et al also suggest one-step diagnostic procedure, though their observation was 
based on different ethnic population (Perucchini et al., 1999).  
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FPG        
(mmol/L) 
Test    
positive 
2- h PG value Macrosomia 
Sensitivity     
(95% CI) 
Specificity      
(95% CI) 
Sensitivity     
(95% CI) 
Specificity      
(95% CI) 
5.0 3.9 
29.1 
(22.9-36.1) 
89.4 
(87.6-91.0) 
21.2 
(12.5-33.3) 
87.2 
(85.0-89.2) 
5.1 3.2 
24.0 
(18.3-30.7) 
93.0 
(91.4-94.3) 
15.2 
(7.9-26.6) 
90.2 
(88.2-91.9) 
5.5 1.8 
13.8 
(9.4-19.6) 
97.4 
(96.3-98.2) 
6.1 
(2.0-15.6) 
95.6 
(94.1-96.7) 
6.1 0.9 
7.1 
(4.1-11.9) 
99.2 
(98.5-99.6) 
1.5 
(0.1-9.3) 
98.2 
(97.1-98.9) 
6.6 0.6 
4.6 
(2.3-8.8) 
99.8 
(99.4-100.0) 
0.0 
(0.0-6.9) 
99.3 
(98.6-99.7) 
2- h PG 7.8 13.4   
13.6 
(6.8-24.8) 
86.3 
(84.0-88.3) 
Table 2. Performance of FPG test for the predictor of gestational diabetes and macrosomia 
5.4 The validation of WHO criterion (DIPSI criterion) based on the fetal outcome 
The authors investigated whether the diagnosis of GDM by WHO criterion is rational based on 
the fetal outcome (N = 1463). Macrosomia was the end point of this study as this is the most 
common morbidity of GDM (Jovanovic, 2001). They observed that there was no statistically 
significant difference in the mean birth weight of neonates born to women in the normal 
glucose tolerance (NGT) and with intervention in GDM groups (P=0.705) (Balaji et al., 2011b). 
This was due to the medical nutrition therapy (MNT) and/or insulin in maintaining FPG ~ 5.0 
mmol/L and 2-h post meal ~ 6.7 mmol/L in GDM women. Intervention helped in maintaining 
the pregnancy outcome in GDM women equivalent to that of NGT women. Gayle et al also 
observed that diagnosis of GDM with OGTT 2-h PG ≥ 7.8 mmol/L and treatment in a 
combined diabetes antenatal clinic is worthwhile with a decreased macrosomia rate and fewer 
emergency cesarean sections (Gayle et al., 2010). The distribution of birth weight of neonates 
born to GDM and NGT women were similar (Figure 2) in the study conducted by the authors, 
indicating that the intervention given to pregnant women with 2-h PG ≥ 7.8 mmol/L had a 
significant effect in obtaining neonatal birth weight appropriate for gestational age. The level 
of association between macrosomia and GDM status after controlling the factors: maternal age, 
gestational age, family history of diabetes and BMI was elucidated. It was found that, the 
GDM status (2-h PG ≥ 7.8 mmol/L) of the pregnant women after intervention was not 
associated with macrosomia (adjusted OR = 0.752; 95% CI (0.406-1.390); P=0.363). There are 
publications confirming that treatment of GDM women as defined by WHO criterion was 
associated with a reduced risk of pregnancy outcome (Crowther et al., 2005; Gayle et al., 2010). 
In pregnancy, the decision to perform a placebo controlled trial requires clinical equipoise 
(Gifford et al., 2001). Hence, in this study, the authors did not have a control group of 
untreated pregnant women with 2-h PG ≥ 7.8 mmol/L, as there are evidences confirming that 
the treatment of GDM women as defined by WHO criterion was associated with a reduced 
risk of pregnancy outcome (Crowther et al., 2005; Gayle et al., 2010). The policy of not treating 
women with 2-h PG ≥ 7.8 mmol/L amounts to deliberately exposing the pregnant mothers to 
unphysiological glycemic level despite our extensive knowledge of the benefits of treatment of 
mild hyperglycemia during pregnancy (Seshiah et al., 2008a; Landon et al., 2009; Bevier et al., 
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1999; Negrato et al., 2008). Wahi et al observed in their prospective study, the advantage of 
adhering to a cut-off level of 2-h PG ≥ 7.8 mmol/L in diagnosis and management of GDM for a 
significantly positive effect on pregnancy outcomes  (Wahi et al., 2011). Fetal exposure to high 
maternal glucose (1-h PG > 7.2 mmol/L with 50g GCT) in the absence of preexisting 
diabetes/GDM may contribute to the development of overweight/obesity in the offspring, 
independent of maternal pre-pregnancy BMI (Deierlein et al., 2011). All these studies validate 
WHO/DIPSI criterion for the diagnosis of GDM 
 
 
Fig. 2. Neonate Birth weight distribution of women with NGT and GDM 
6. Gestational weeks for screening 
The current recommendation is to perform screening test between 24 - 28 weeks of gestation, 
though there are reports that claim, about 40% to 66% of women with GDM can be detected 
early during pregnancy (Super et al., 1991; Nahum et al., 2002). Nahum et al also suggest 
that the ideal period to screen for GDM is around 16 weeks of gestation and even earlier in 
high-risk groups with a history of fetal wastage (Nahum et al., 2002). This is due to the 
embryological development of fetal β cells. Each islet cell functions as an endocrine organ 
and differentiates between 10th and 12th weeks of gestation. They recognize and respond to 
maternal glycemia before 15 weeks of gestation, suggesting that metabolic perturbations are 
underway before diagnosis and that earlier screening and intervention may be warranted 
(Tisi et al., 2011). The study performed by the present authors group in the DIPAP project 
revealed that, 16.3% had glucose intolerance within 16 weeks, 22.4% between 17 - 23 weeks 
and remaining 61.3% more than 24 weeks of gestation (Seshiah et., 2007). If a pregnant 
woman has an A1c level > 6%, she is more likely to be an overt diabetic (Balaji et al., 2007). 
These studies stress the need for screening for GDM during the early weeks of gestation. If 
the test is normal in the first visit, the test has to be repeated in the subsequent visits. GDM 
diagnosis may not be missed by screening around 24 -28 weeks of gestation, but a 
substantial number of pregnant women who develop GDM in the earlier weeks of 
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pregnancy are likely to have delayed diagnosis and may not receive appropriate medical 
care. Further, early screening for glucose intolerance and care could avoid some diabetes 
related complications in women with gestational diabetes (Bartha et al., 2003). To 
substantiate the above observation the present author’s group screened 207 pregnant women 
attending their referral centre for diabetes and pregnancy with a 75g OGTT (Seshiah et al., 
2006). Among them, 87 (42.03%) were diagnosed with GDM. Women in whom GDM was 
detected between 0 - 23 weeks of gestation were classified as Group 1 [54 (62.7%)] and beyond 
24 weeks of gestation as Group 2 [33 (37.93%)]. All of them were treated and followed till 
confinement. There was no statistically significant difference (P < 0.05) between the birth 
weight of the neonates born to Normal Glucose Tolerance (NGT) women (3.28  0.50 kg) and 
GDM women in group 1 (3.13 ± 0.55 kg). In group 2, the neonatal birth weight was 3.42 ± 0.58 
kg which is the upper limit of the normal range in Indian new born babies. In India, the 
normal birth weight varies between 2.5 to 3.5 kg (Paul et al., 2002). The observation of this 
study was that, by early detection of glucose intolerance during pregnancy and by giving 
adequate care to the antenatal women, a good fetal outcome can be achieved similar to that of 
NGT pregnant women (Seshiah et al., 2006, 2008b).  
7. Management  
The goal in the management is to avoid both low birth weight and macrosomic babies, as 
they are prone to develop diabetes in their adolescent and adult life (Jovanovic, 1998). In 
India, both under nutrition and over nutrition exists during pregnancy. There are two 
reported studies in India that relates size at birth to future risk of type 2 DM. In Mysore, low 
birth weight did not increase the risk of diabetes but babies who were short and fat at birth 
(higher BMI) were at increased risk (Fall et al., 1998). Fall et al speculate that the rise in type 
2 DM in Indian urban populations would have been triggered by mild obesity in mothers, 
leading to glucose intolerance during pregnancy, macrosomic changes in the fetus and 
insulin deficiency in adult life (Fall et al., 1998). Yet another study attributes high prevalence 
of type 2 DM and IGT in Indian people linked to poor fetal growth (Yajnik et al., 1995) 
which is at variant to Fall et al observation (Fall et al., 1998).   
7.1 Medical Nutrition Therapy (MNT)  
The meal pattern should provide adequate calories and nutrients to meet the needs of 
pregnancy metabolism. The meal plan advised has to be simple and easy to practice. The 
MNT recommended is based on their routine diet habit and glycemic excursions that occur 
with the meal. In a normal person, the peaking of the plasma glucose is high after breakfast 
(due to ‘Dawn phenomenon’) than after lunch and dinner, and the insulin secretion also 
matches the glycemic excursions that occur with these three meals (Polonsky et al., 1988). 
Since GDM mothers have deficiency in first phase insulin secretion, the quantity of food at 
one time should also be less, to overcome this insulin deficiency, particularly after breakfast. 
To avoid the post prandial plasma glucose peaking with breakfast, the authors guide their 
women with GDM to distribute calorie consumption especially the breakfast into two 
portions ‘Split Breakfast’. This implies splitting the usual breakfast into two halves and 
consuming these portions with a two-hour gap in between. By this, the undue peak in 
plasma glucose levels after ingestion of the total quantity of breakfast at one time is avoided.  
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7.2 Insulin therapy  
7.2.1 Human insulin  
The policy followed in India is to advise human insulin in women with GDM who failed to 
achieve FPG of ≤ 5.0 mmol/L and 2-h post meal plasma glucose level of ≤ 6.7 mmol/L with 
MNT. The aim is to maintain post meal peak plasma glucose level of ≤ 6.7 mmol/L. This 
time point is suggested as the diagnosis of GDM is made with 2-h PG and it is easy to 
remember the same timing. A number of studies have established the benefits of 
maintaining the plasma glucose at this level (Franks et al., 2006; de Sereday et al., 2003; Ben-
Haroush et al., 2004). However whichever time is targeted for monitoring glycemic control 
and adjusting the insulin dose, the blood tests have to be done at the same time at each visit.  
GDM women usually have high post breakfast plasma glucose level compared to post lunch 
and post dinner. The period between breakfast and lunch are often problematical because of 
the physiological tendency to hyperglycemia at this time and may necessitate substantial 
increases in the morning dose of short acting insulin, together with careful adjustment of 
meal timing and snacks to avoid pre-lunch hypoglycemia (Langer et al., 2000).  
7.2.2 Insulin analogues  
Due to the pharmacokinetic action of human regular insulin, a considerable segment of 
pregnant women with GDM, fail to achieve optimum glycemic control, mostly the post 
prandial plasma glucose. In them, the best option is to administer ultra short acting 
analogues, insulin lispro (Humalog) or insulin aspart (Novo rapid). These analogues 
improve the post prandial glucose control in pregnant women with type 1, type 2 DM and 
GDM, and are also safe and effective (Hermansen et al., 2002; Jovanovic et al., 1999). 
The authors group conducted an open label trial using a large independent cohort of GDM 
patients to evaluate the efficacy, safety and foetal outcome for Biphasic Insulin aspart (BIAsp 
30) compared with biphasic human insulin (BHI 30) in the management of GDM (Balaji et al., 
2010). GDM women (N = 323) who remained unable to maintain a FPG ≤ 5.0 mmol/L and 2-h 
PG ≤ 6.7 mmol/L with MNT were randomly allocated in a 1:1 ratio to receive either BIAsp 30 
(Group A) or BHI 30 (Group B). There was no statistical significance in the levels of glycaemic 
control achieved by the groups by labour onset. However, the mean total insulin dose 
administered by the last visit was significantly lower for Group A [19.83±15.75 U compared 
with 26.34±23.15 U for Group B (p=0.006)], implying that those receiving BHI 30 required a 
higher dose to achieve a similar degree of glycaemic control. The frequency of macrosomia 
was 6.3% in Group A and 6.9% in Group B. Although the proportion of macrosomia was 
numerically higher for Group B than Group A, the difference was not statistically significant 
(p=0.819). It was found that BIAsp 30 was non-inferior to BHI 30 and was well tolerated during 
pregnancy. Yet in another study, the authors observed that pregnant women found BIAsp 
convenient as this preparation allows flexibility in the meal time insulin dosing and did not 
disturb their routine life pattern. Most importantly, BIAsp was found to be safe during 
pregnancy (Balaji et al., 2010). 
7.3 Oral hypoglycemic agents  
7.3.1 Glibenclamide 
Glibenclamide (Glyburide) may be an alternative safe therapy for many GDM women who 
are hesitant to take insulin. This drug decreases the insulin resistance and improves insulin 
secretion, the pathogenic factors in the causation of hyperglycemia in GDM (Groop et al., 
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1991; Rossetti et al., 1990). Another advantage is that, the human placental transfer of 
glibenclamide is negligible. Maternally administered glibenclamide in pharmacologic doses, 
and even doses greatly exceeding therapeutic levels, may not reach the fetus (Elliott et al., 
1991). The landmark study of Langer et al concluded that glyburide was as effective as 
insulin in maintaining the desired glycemic levels and resulted in a comparable outcome 
(Langer et al., 2000). The author’s group undertook a prospective study comparing insulin 
and glibenclamide in GDM. In this study, both Glibenclamide and insulin treatment 
achieved equally good glycemic control and the perinatal outcome was not different 
(Anjalakshi et al., 2007). The observation of this study was that the mean dose of 
glibenclamide required at term was 1.45 ± 0.57 mg/day and mean insulin requirement at 
term was 21.7 ± 13.55 units/day to achieve the same glycemic level (Anjalakshi et al., 2007). 
It is noteworthy that Glibenclamide is very much economical and cost effective compared to 
insulin, which is not only expensive but also inconvenient as it has to be taken parenterally. 
Yet an another observation was that in Indian population, the dose of glibenclamide 
required is very much less compared to the other published studies (Langer et al., 2005).   
7.3.2 Metformin 
Women with polycystic ovary syndrome (PCOS) are advised metformin to induce 
ovulation. The drug is not withdrawn if a woman conceives while on metformin therapy 
and the maximum dose prescribed in the author’s clinical practice is 1500 mg.  If the plasma 
glucose is not under control with metformin, insulin is always added. No adverse 
pregnancy outcome with metformin therapy was observed. A preliminary study showed 
that metformin was safe in pregnant, glucose intolerant women either as an adjunct to 
insulin treatment or even as a monotherapy (Ramachandran et al., 2005). A prospective 
study found no adverse influence on the pregnancy outcome in PCOS women treated 
throughout pregnancy with Metformin (Glueck et al., 2004).  
Metformin in gestational diabetes (MiG) trial found that in women with gestational diabetes 
mellitus, metformin (alone or with supplemental insulin) was not associated with increased 
perinatal complications as compared with insulin (Rowan et al., 2008).  
8. Monitoring glycemic control 
The success of the treatment for a woman with GDM depends on the glycemic control 
maintained with meal plan or pharmacological intervention. To know the effectiveness of 
treatment, monitoring of glycemic control is essential.  
 Once diagnosis is made, medical nutritional therapy (MNT) is advised initially for two 
weeks. If MNT fails to achieve control i.e., FPG ≥ 5.0 mmol/L and/or 2-h PG ≥ 6.7 
mmol/L, insulin may be initiated. 
 Once target blood glucose is achieved, woman with GDM till the 28th week of gestation 
require laboratory monitoring of both fasting and 2-h post breakfast once a month and 
at other time of the day as the clinician decides. 
 After the 28th week of gestation, the laboratory monitoring should be more frequent 
atleast once in 2 weeks, if need be more frequently. 
 After 32 weeks of gestation, laboratory monitoring should be done once a week till 
delivery 
 In high risk pregnancies, frequency of monitoring may be intensified with self 
monitoring of blood glucose (SMBG). 
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 Continuous glucose monitoring devices are available but these equipments need special 
training and are expensive. These devices may be useful in high risk pregnancies to 
know the glycemic fluctuations and to plan proper insulin dosage. 
8.1 Glycosylated haemoglobin – A1c levels  
If the glucose intolerance is detected in the early pregnancy, A1c level will be helpful to 
differentiate between a pre gestational diabetic and GDM. If A1c level is more than 6% 
(Balaji et al., 2007), the chances are that she may be a pre GDM or GDM, in whom the 
glucose intolerance was detected in the early weeks of pregnancy; all the more validating 
that the screening needs to be performed in the early weeks of gestation. The estimation of 
A1c may help in distinguishing a pre GDM from an early onset GDM, but not essential, as 
this differentiation is of no consequence in clinical practice, as the treatment approach is 
going to be the same (Seshiah et al., 2007). Further, A1c is not estimated in the community 
health centres, barring a few tertiary care hospitals due to the difficulty in standardization, 
inadequate technical support and the cost.  
8.2 Measuring other parameters 
The blood pressure has to be monitored during every visit. Examination of the fundus and 
estimation of microalbuminuria, every trimester is recommended. 
8.3 Ultrasound fetal measurement  
The management of gestational diabetes, based on the foetal growth by ultrasonogram 
demands that the fetus at risk must first manifest overgrowth before treatment decisions are 
made. Further, the cost of performing a number of ultrasonograms to monitor the foetal 
growth and recommending therapy has to be kept in mind. Until there is evidence to 
absolutely prove that ignoring maternal hyperglycemia when the fetal growth patterns 
appear normal on the ultrasonogram, it is prudent to achieve and maintain normoglycemia 
in every pregnancy complicated by gestational diabetes.  
9. Target glycemic level 
Increased birth weight of neonates occurred even when the mother’s glucose tolerance was 
less than the glycemic criteria recommended by WHO (2-h PG > 7.8 mmol/L) for diagnosis 
of GDM. Increasing carbohydrate intolerance in women without overt GDM was associated 
with graded increase in the incidence of macrosomia (Sermer et al., 1998). The author’s 
group documented that the occurrence of macrosomia was continuum as the FPG increased 
> 5.0 mmol/L (Seshiah et al., 2008c) and the 2-h PG > 6.7 mmol/L (Balaji et al., 2006). Thus 
maintenance of mean plasma glucose level ~ 5.8 to 6.1 mmol/L is desirable for a good fetal 
outcome (Langer et al., 1989). This is possible if FPG and peak postprandial glucose levels 
are maintained ~ 5.0 mmol/L (4.4-5.0 mmol/L) and ~ 6.7 mmol/L (6.1 – 6.7 mmol/L, 
respectively) 
10. Prevention of type 2 dm 
The screening for glucose intolerance during pregnancy is not done routinely and probably 
the undiagnosed glucose intolerance that has been occurring in the past has resulted in the 
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increased prevalence of diabetes in India. This is likely to be true as GDM has a far reaching 
consequence in predisposing their offsprings to glucose intolerance. This observation was 
substantiated and documented in Pima Indians (Dabelea et al., 2000). The children born in 
1965 to women with GDM were followed up till 2000. By the time they reached 35 years, 
more than half of the group had diabetes (Dabelea et al., 2000). Hence as a policy to identify 
GDM and its consequences on the infant, a 75 g OGTT has been recommended to all women 
in the population during the third trimester of pregnancy (Dabelea et al., 2000). Now it is 
obvious that taking care of women with GDM is the first step in the primary prevention of 
diabetes.  
The important aspect of diabetes and pregnancy is that, the intrauterine millieu interieur, 
whether one of nutritional deprivation or one of nutritional plenty, results in changes in 
fetal pancreatic development and peripheral response to insulin that may lead to adult-
onset GDM and type 2 DM (Savona-Ventura & Chircop, 2003). Thus, the timely action taken 
now in screening all pregnant women for glucose intolerance, achieving euglycemia in them 
and ensuring adequate nutrition may prevent in all probability, the vicious cycle of 
transmitting glucose intolerance from one generation to another (Aerts, 2004). GDM offers 
an important opportunity for the development, testing and implementation of clinical 
strategies for diabetes prevention (Buchanan et al., 2007). 
‘No single period in human development provides a greater potential than pregnancy for a 
long range pay off via relatively short range period of enlightened metabolic manipulation’ - 
Norbert Frienkel.  
11. Summary  
 GDM women are at increased risk of future diabetes as are their children and following 
generations.  
 Prevalence of GDM varies from one region to another region in the same country. 
 Compared with selective screening, Universal screening for GDM detects more cases 
and improves maternal and offspring prognosis.  
 Asian women are ethnically more prone to develop glucose intolerance compared to 
other ethnic groups. 
 GDM based on 2-h 75g OGTT defined by WHO predicts adverse pregnancy outcome 
and warrants treatment. 
 A 2-h 75g post plasma glucose ≥ 7.8 mmol/L serves both as screening and diagnostic 
criteria which is a technically simple economical and evidence based one step 
procedure.   
 IADPSG recommendations are suitable in clinical settings where technical and financial 
supports are available.  
 Early screening for glucose intolerance and care could avoid some diabetes related 
complications in women with gestational diabetes 
 Women with NGT in the first visit are advised to undergo glucose tolerance test in the 
subsequent trimesters. 
 The meal pattern advised has to be simple, and easy to understand and follow. 
 The goal is to maintain mean plasma glucose of 5.8 to 6.1 mmol/L 
 Occurrence of macrosomia was continuum as the FPG increased from 5.0 mmol/L and 
2-h PG increased from 6.7 mmol/L. 
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 At least one point testing in the third trimester of measuring haemoglobin, blood 
pressure and plasma glucose in pregnant women will go a long way in achieving safe 
maternal and fetal outcome.  
 Taking care of women with gestational diabetes is envisaged as the first step in the 
primary prevention of diabetes. 
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